Fosfomycin Aristo

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fosfomycin Aristo

Quick Facts

Property Description
Active ingredient Fosfomycin (typically as the trometamol salt)
Form Powder for oral solution (sachet)
Pharmacological class Antibiotic, Epoxide class, Anti-Bacterial Agent
General purpose Clearing specific bacterial infections (Urinary Tract)
Origin Synthetic derivative (Phosphonic acid)

What Type of Antibiotic is Fosfomycin and What is its Purpose?

Fosfomycin Aristo is a pharmaceutical preparation containing the active ingredient Fosfomycin, which is formally classified as an Antibiotic and a highly specific Anti-Bacterial Agent. It belongs to the unique epoxide class of antibiotics, a category distinct from most conventional antibiotic groups. Its primary designation is as a Urinary Anti-Infective Agent because it achieves highly effective concentrations in the urinary tract.

The purpose of this agent is to eliminate susceptible bacterial infections; it is clinically recognized for its activity against multi-resistant strains. Its distinct mechanism of action is beneficial in avoiding common bacterial resistance pathways. The substance, which is a synthetic phosphonic acid derivative, is utilized for the treatment of infections caused by difficult-to-treat organisms.


Composition, Delivery Type, and Distinctive Action

The product Fosfomycin Aristo delivers the active ingredient Fosfomycin, typically as the trometamol salt, via the oral route of administration. As a registered product of Aristo Pharma, this specific preparation is a single active ingredient preparation, often used in scenarios involving acute uncomplicated cystitis. It is presented as a powder for oral solution sachet, which is prepared by dissolution in water for consumption.

Fosfomycin is notable for its powerful bactericidal effect, meaning it actively and irreversibly kills the targeted bacteria rather than merely inhibiting their growth. Its physiological action involves blocking the very first committed step in the biosynthesis of the bacterial cell wall. This specific disruption of the core cell structure allows the agent to provide rapid and targeted clearance of the infection.

Regulatory References

  1. World Health Organization (WHO)

What side effects are possible with Fosfomycin Aristo?

Possible Side Effects and Safety Information

Fosfomycin Aristo's safety profile, based on regulatory documentation, classifies potential adverse reactions by frequency and the body system affected. Most reported effects are generally temporary and self-limited in duration.

Frequency-Classified Adverse Reactions

The table below outlines the officially documented side effects, organized by the system they affect (System-Organ Class or SOC) and their reported frequency in clinical use:

Frequency Classification System-Organ Class Officially Listed Effects
Common (1/100 to 1/10) Gastrointestinal disorders Diarrhoea, Nausea, Abdominal pain, Dyspepsia
Nervous system disorders Headache, Dizziness
Infections and infestations Vulvovaginitis
Uncommon (1/1,000 to 1/100) Gastrointestinal disorders Vomiting
Skin/subcutaneous tissue Rash, Urticaria, Pruritus

Serious Adverse Reactions and Safety Constraints

The regulatory profile highlights rare but clinically significant risks. Serious adverse reactions that have been documented include anaphylactic reactions (severe, systemic allergic response that may result in shock), Angioedema, and severe Antibiotic-Associated Colitis (including Clostridioides difficile-associated diarrhea or CDAD).

CDAD may occur late, even two months or more after the medication is discontinued.

Regulatory documentation also defines specific constraints for use. The medicine is contraindicated in patients with a known hypersensitivity to the drug. Furthermore, it is contraindicated for patients with severe renal impairment (creatinine clearance less than 10 mL/min) due to the potential for drug accumulation. Safety and effectiveness are not established for pediatric patients aged 12 years and under.

Overdose and Emergency Response

Overdose and when to seek help

Overdose scope

Feature Regulatory Documentation
Documented overdose presentations Overdose is officially associated with specific sensory effects documented in regulatory reports, including impaired hearing and vestibular loss, which affects balance. Additional reported clinical signs include a general decline in taste perception and the presence of a metallic taste. These findings are linked to exposure significantly exceeding the single labeled dose.
Emergency-response statements (as written in official documents) In the event of a suspected or confirmed overdose, regulatory guidance mandates that the individual seek emergency medical attention immediately. Urgent help is required when an overdose is suspected, necessitating prompt contact with a national Poison Help line or local emergency services.

Overdose classifications (high-level)

Classification Feature Regulatory Documentation
Severity classification (as defined in official documents) The officially classified symptoms concentrate on these sensory effects as the primary documented consequence of overdose.
Overdose-context constraints (as defined in official documents) Treatment management is strictly constrained to symptomatic and supportive treatment because official prescribing information states that no specific antidote is known for Fosfomycin overdose.

Resulting overdose structure

Official overdose statements:

  • Supportive management is required to promote the drug’s elimination.
  • This procedure specifically involves the adequate administration of oral fluids to facilitate the urinary excretion of the drug from the body.

Therapeutic Uses of Fosfomycin Aristo

What Fosfomycin Aristo Treats: Main Uses and Benefits

The oral formulation of Fosfomycin is officially recognized for its role as an anti-infective agent for the lower urinary tract. The treatment is commonly used for acute, uncomplicated cystitis in women and adolescent girls. This defines the primary therapeutic domain of the medication.

Fosfomycin Aristo is generally used for managing conditions characterized by periods of heightened symptoms, such as bacterial cystitis. It is applied in clinical settings for the management of infections caused by susceptible bacterial pathogens, including those demonstrating multi-drug resistance. This approach helps address the distressing symptom cluster associated with acute bladder infection, including dysuria (painful urination), urinary urgency, and frequency.

By supporting the clearance of the infection, it contributes to easing the overall symptom burden.

“The therapeutic approach is focused on supporting the resolution of the acute infection and easing symptomatic distress.”

Therapeutic Focus: Acute Symptom Support

Feature Therapeutic Focus
Primary Condition Acute uncomplicated bacterial cystitis
Symptoms Relieved Painful urination, urgency, and frequency
Key Benefit Supports pathogen clearance; helps improve day-to-day comfort
Clinical Context Outpatient treatment for lower UTIs

Eligibility and Restrictions for Use

The eligibility for using the oral single-dose formulation of Fosfomycin Aristo (Fosfomycin trometamol) is strictly defined by regulatory documents, primarily for female patients with uncomplicated lower urinary tract infections.

Eligibility Scope

Classification Population/Condition
Allowed Use Adult women and female adolescents (aged 12 years and older)
Not Indicated Male patients or patients with upper urinary tract infections (e.g., pyelonephritis)
Not Recommended Children below 12 years of age (safety/efficacy not established)
Contraindicated Patients with known hypersensitivity to fosfomycin
Contraindicated Patients with severe renal impairment ( CrCl < 10 mL/min)

Additional Constraints

  • Pregnancy/Lactation: Use during pregnancy or breastfeeding is only permitted if considered clearly necessary by a healthcare provider.
  • Metabolic Disorders: The product is contraindicated in patients with excipient-related issues, such as hereditary fructose intolerance, due to the presence of sucrose in the oral granules.

These official regulatory statements establish clear boundaries, indicating that use is strictly restricted to uncomplicated cases in the approved age and gender groups.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Pharmacokinetic Interactions and Avoidance Rules

Co-administration with agents that increase gastrointestinal motility, such as metoclopramide and other prokinetics, should be avoided. This is a formal regulatory constraint due to a documented pharmacokinetic interaction that causes a lowering of Fosfomycin’s serum concentrations and overall urinary excretion.

The regulatory profile also includes a documented risk for co-administration with Oral Anticoagulants (e.g., Warfarin). As a class, anti-bacterial agents are reported to potentially cause an increase in oral anticoagulant activity, which can result in an alteration of the International Normalized Ratio (INR).

For the agent Cimetidine, official regulatory studies formally document that co-administration does not affect the pharmacokinetics of Fosfomycin.

Food and Administration Timing

Administration of the product with food is documented to cause a delay in absorption and a resultant slight decrease in the drug's peak plasma levels. Due to this pharmacokinetic effect, official labeling recommends taking the product on an empty stomach or with a minimum separation of two to three hours after meals.

Population-Specific Risk

Severe renal impairment (creatinine clearance <10 mL/min) is explicitly noted in official labeling as a condition that significantly decreases the excretion of Fosfomycin, leading to the risk of drug accumulation in this specific population.

Mechanism of Action

How Fosfomycin Aristo Works


Active Uptake and Enzyme Inhibition

This section details how the drug gains entry into the bacterial cell and the specific molecular target it inactivates.

Fosfomycin begins its action by being actively transported into the bacterial cytoplasm using the bacteria's own nutrient systems, specifically the GlpT and UhpT transporters. Once inside, it acts as an irreversible covalent inhibitor of the enzyme MurA (UDP-N-acetylglucosamine enolpyruvyl transferase). This permanent inactivation of the enzyme constitutes the initial molecular step in the causal cascade leading to bacterial cell death.


Disruption of Peptidoglycan Precursor Synthesis

This section explains the resulting failure of the bacterial pathway and the structural consequence for the pathogen.

By permanently blocking the MurA enzyme, the drug arrests the very first committed step in the peptidoglycan biosynthesis pathway. This prevents the creation of essential cell wall building blocks, which ultimately leads to a fundamental structural failure of the bacterial cell wall. This failure means the pathogen cannot withstand its own internal osmotic pressure, leading to cell lysis and death, which constitutes the bactericidal physiological consequence of the mechanism.

Dosage and Administration Information

How to Use Fosfomycin Aristo

The administration of Fosfomycin Aristo, which contains the active ingredient Fosfomycin (as the trometamol salt), is structured as a standardized, single-dose oral regimen. The product is supplied as a powder for oral solution and is exclusively intended for the oral route of administration.

Official Dosing and Frequency

The standard course for the main approved use requires the administration of a single dose of 3 grams of Fosfomycin. This single dose constitutes the entirety of the treatment and requires no follow-up administrations. This specific regimen is used for the management of acute uncomplicated cystitis in adult women and in adolescent girls (typically from 12 years of age).

Preparation and Administration Conditions

For proper use, the entire contents of the sachet must be fully dissolved in a glass of water before being consumed. To optimize absorption, the drug is taken on an empty stomach, meaning approximately two to three hours before or after a meal. It is common practice to recommend taking the dose at bedtime and specifically after the bladder has been emptied to permit the maximum concentration time in the urinary tract.

Special Population Considerations

The 3 g dose is standard for approved populations, but the drug is primarily eliminated by the kidneys. Therefore, administration may require adjustment or be contraindicated in patients with severe renal impairment (low creatinine clearance).

Recent Clinical Evidence

Research Evidence / Overview of Studies for Fosfomycin Aristo


Evidence for Use in Acute Uncomplicated Cystitis (AUC)

Research has primarily examined Fosfomycin Aristo in individuals who were included based on having lower urinary tract infection symptoms, representing conditions involving periods of heightened symptoms related to acute, uncomplicated bladder infections. These studies, which include Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews, focus on adult women and adolescent girls. Researchers monitored several outcomes related to physical discomfort, such as the evolution of painful urination, urinary urgency, and frequency, alongside microbiological status, specifically the presence or absence of the target bacteria in the urine, as measured in the studies.

The findings describe patterns observed in the studies regarding the monitored endpoints, including microbiological status (the measured presence or absence of the target bacteria) and the evolution of patient-reported symptoms during the observation period. Research explored short-term symptom changes, often tracking the patient's condition for around seven to ten days after this type of administration. These initial results were then followed up to monitor for recurrence of the infection at intermediate intervals, commonly around 28 to 30 days.

Studies in Cases Involving Multi-Drug Resistant (MDR) Pathogens

Separate research was evaluated in settings involving bacterial infections that are more difficult to treat, specifically those caused by Multi-Drug Resistant (MDR) bacteria. These studies explored whether the unique mechanism of action of the drug was associated with the measured clinical and microbiological outcomes in these complex scenarios. The evidence in this area contributes to the broader evidence landscape by showing what has been observed so far in populations studied because of difficulty treating MDR infections.


Long-Term Follow-up and Durability of Effect

While the duration of observation in the key clinical trials was limited, primarily focusing on research exploring short-term symptom changes, long-term effects are not fully established. There is limited information for long-term outcomes that track the maintenance of the microbiological status and the rate of infection recurrence beyond the first few months. Therefore, data are still emerging regarding the sustained response over a longer duration.

Understanding the Strengths and Limitations of the Evidence

The research base includes a number of Randomized Controlled Trials (RCTs), which are considered a high-quality study design, and these trials help contextualize how patients reported their experience of this acute infection. However, researchers have noted several limitations. For example, the follow-up durations were limited primarily to one month, and some sample sizes were modest in the earlier studies. Additionally, while the drug's research is based on a specific administration format, there can be continued scientific discussion regarding whether this specific administration approach is adequate for managing all scenarios, particularly those involving more resistant bacteria. The evidence highlights what is known — and what is still uncertain — and confirms that the research does not determine whether an individual will respond similarly to the group findings.

Key Studies & References

  1. World Health Organization (WHO) Expert Committee on Selection and Use of Essential Medicines

Frequently Asked Questions (FAQ)

Common questions about Fosfomycin Aristo (FAQ)


Q: How quickly does Fosfomycin Aristo start to work?

Regulatory information indicates that the drug is rapidly absorbed after being taken orally. It reaches its maximum concentration in the blood within approximately two hours when taken on an empty stomach. Label information indicates it quickly achieves high concentrations in the urine, which is the site of the infection.


Q: Do I need a prescription to get Fosfomycin Aristo?

Yes, official regulatory documents confirm that Fosfomycin trometamol is classified as a prescription-only medicine (Rx only). This means it can only be dispensed by a pharmacy with a valid prescription from a qualified healthcare professional.


Q: Is Fosfomycin Aristo considered a strong antibiotic?

Official information describes Fosfomycin as a bactericidal agent, which means its action results in bacterial cell death. It has a broad range of activity against the specific microorganisms that cause urinary tract infections. This activity is recognized for its unique mechanism of action that is distinct from many other antibiotic classes.


Q: Why is Fosfomycin Aristo often only a single dose?

The drug is eliminated slowly by the body, a factor that contributes to the single-dose regimen. Studies show that Fosfomycin maintains high concentrations in the urine—the site of the infection—for at least 24 hours. This sustained level is adequate to fight the bacteria, making follow-up administrations typically not required for the approved use.


Q: How long does the effect of a single dose of Fosfomycin Aristo last?

The drug is designed to sustain its action over a prolonged period. The key is that the concentration of the drug remains at effective levels in the urine for at least 24 hours after administration. These sustained levels in the urine are associated with the drug's activity throughout the duration of the approved regimen.


Q: Is it safe for older adults (seniors)?

Official labeling states that no dosage adjustment is necessary for elderly patients based on age alone. However, due to the drug's elimination via the kidneys, its use in older patients with severe renal impairment is subject to regulatory constraints.


Q: What type of bacteria is Fosfomycin Aristo effective against?

The drug is described in regulatory documents as active against the pathogens most commonly responsible for uncomplicated urinary tract infections. Regulatory documents specifically state it is effective against most strains of Escherichia coli (E. coli) and Enterococcus faecalis.


Q: Is Fosfomycin Aristo the same as other Fosfomycin brand names?

Fosfomycin Aristo delivers the same active ingredient, which is Fosfomycin tromethamine, as other branded and generic versions of the single-dose oral solution. Although packaging and excipients may vary, the core therapeutic component is identical.


Q: Why is Fosfomycin Aristo sometimes preferred over other UTI antibiotics?

Official product information describes several characteristics that may be a factor in its use. These include its unique mechanism of action, which avoids common bacterial resistance pathways, its single-dose regimen, and its established activity against certain resistant pathogens.


Q: Is there a generic version of Fosfomycin Aristo?

Yes, official regulatory sources, such as the FDA’s generic listings, show that several manufacturers have received approval to market generic versions of the active ingredient, Fosfomycin tromethamine.


Q: How does Fosfomycin Aristo travel through the body?

After being absorbed into the blood, the drug is primarily distributed to the kidneys and the wall of the bladder, which is where the drug's activity is primarily concentrated. It is excreted from the body largely unchanged through both the urine and the feces.


Q: Can I take pain relievers like ibuprofen with Fosfomycin Aristo?

Official regulatory documents do not list a specific contraindication or interaction warning for pain relievers such as ibuprofen. However, individuals are advised to refer to the official prescribing information for a complete list of known drug interactions.


Q: Is the bitter taste of the dissolved powder normal?

The active ingredient, Fosfomycin tromethamine, is described as having a salty taste. Users commonly report a taste sensation that may be perceived as bitter or strong when the powder is fully dissolved in water for consumption.


Q: What if my symptoms don't fully go away after taking Fosfomycin Aristo?

Official warnings in regulatory documents indicate that if symptoms persist, worsen, or return after taking the medication, official documents recommend re-evaluation by a healthcare provider. This may indicate an infection caused by a resistant pathogen or a more serious upper urinary tract infection.


Q: How is Fosfomycin Aristo different from the intravenous (IV) form of fosfomycin?

The oral product (Fosfomycin Aristo) is the tromethamine salt and is officially approved as a single dose for uncomplicated UTIs. In contrast, the intravenous form is a different salt (disodium) and is generally used for complicated infections, which requires different administration schedules and potentially specific monitoring.


Q: Is Fosfomycin Aristo commonly used outside of Europe/the US?

Yes, official regulatory documents from various jurisdictions confirm the drug's widespread use. Fosfomycin trometamol has been available for the treatment of lower UTIs in many countries, including the US, UK, Canada, and Australia, for several decades.


Q: Are there any warnings about taking this drug if I have a history of liver issues?

Official literature indicates that Fosfomycin is not metabolized by the liver, which is a factor noted in its metabolic profile. As a result, regulatory documents do not state a formal contraindication for patients with liver issues.


Q: What happens if I accidentally take two doses close together?

Official regulatory information on overdose indicates that a specific antidote is not available. Official documents state that management of an accidental overdose would involve symptomatic and supportive care, as there is no specific antidote.


Q: Does Fosfomycin Aristo contain lactose or gluten?

The official product information lists sucrose (sugar) as an excipient, which creates a contraindication for individuals with hereditary fructose intolerance. Specific mention of the presence or absence of lactose or gluten is generally not a uniform regulatory requirement for this specific formulation.


Q: Is there a risk of antibiotic resistance with Fosfomycin Aristo?

Official documents describe how bacteria may develop resistance to Fosfomycin. The resistance mechanism primarily involves a genetic change that alters the bacterial transport systems used to carry the drug into the cell, thereby preventing the drug from reaching its target.


Q: Is it safe to drive after taking Fosfomycin Aristo?

Official product labeling indicates that Fosfomycin can cause side effects such as dizziness. These central nervous system effects may affect a patient’s ability to drive or safely operate machinery.


Q: Does this antibiotic affect gut flora much?

Like many antibiotics, Fosfomycin is associated with gastrointestinal side effects such as diarrhea. Regulatory information confirms that this drug may rarely cause severe Antibiotic-Associated Colitis, a serious condition that results from a significant disruption to the normal intestinal flora.


Q: Is it described as being a 'broad-spectrum' antibiotic?

Yes, Fosfomycin is formally described in regulatory-linked documents as a broad-spectrum antibiotic. This refers to its documented activity against a wide range of both gram-positive and gram-negative microorganisms.

How should Fosfomycin Aristo be stored and disposed of?

Official Storage and Disposal Requirements

This information reflects the official storage, handling, and disposal instructions for Fosfomycin Aristo (fosfomycin trometamol) as documented in regulatory labeling.

Storage Component Requirement
Temperature Store at or below 25 C (room temperature).
Protection Protect from heat, light, and moisture. Do not freeze.
Packaging Keep the medicine in its original, tightly closed sachet and carton.
Child Safety Keep out of the reach of children and pets.
Stability The dissolved product must be taken immediately after preparation.

Unused or expired Fosfomycin Aristo must be disposed of in accordance with local regulations and environmental protection requirements. Do not discard the medication in household trash or pour it into wastewater, to avoid environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fosfomycin Aristo found in:

A-Z Index: